O

Oryzon Genomics
ORY

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
€218.20M
EV
€228.79M
Shares Outstanding
77.51M
Beta
0.44

Wall Street View

Analyst Rating
BUY
Analyst Target Price
€6.78
P/E 2025E
11.04x
P/Revenue 2025E
8.25x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Oryzon Genomics S.A.

gainify

O

Oryzon Genomics S.A.

ORY

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhib...

Sector

Healthcare

Industry

Biotechnology

CEO

Arjol, Carlos Manuel

Employees

47

IPO Date

2015-12-14

Headquarters

Sant Ferran 74, Cornellà de Llobregat, Catalonia, 08940, Spain

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.